keyword
MENU ▼
Read by QxMD icon Read
search

HCV guidelines

keyword
https://www.readbyqxmd.com/read/28930859/p16-methylation-was-associated-with-the-development-age-hepatic-viruses-infection-of-hepatocellular-carcinoma-and-p16-expression-had-a-poor-survival-a-systematic-meta-analysis-prisma
#1
Xueyou Lv, Guoliang Ye, Xinjun Zhang, Tao Huang
BACKGROUND: Loss of tumor suppressor gene p16 expression via promoter methylation has been reported in hepatocellular carcinoma (HCC). This meta-analysis was conducted to evaluate the correlation between p16 methylation and HCC. Additionally, we also analyzed the potential prognostic role of p16 methylation, expression or alteration-associated HCC. METHODS: Online databases based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline were performed to analyze the role of p16 gene in HCC...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28929515/treatment-of-hepatitis-c-virus-infection-with-direct-acting-antiviral-drugs-is-safe-and-effective-in-patients-with-hemoglobinopathies
#2
Raffaella Origa, Maria Laura Ponti, Aldo Filosa, Alfonso Galeota Lanza, Antonio Piga, Giorgio Maria Saracco, Valeria Pinto, Antonino Picciotto, Paolo Rigano, Salvatore Madonia, Rosamaria Rosso, Domenico D'Ascola, Maria Domenica Cappellini, Roberta D'Ambrosio, Immacolata Tartaglione, Lucia De Franceschi, Barbara Gianesin, Vito Di Marco, Gian Luca Forni
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few...
September 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28926561/mechanisms-of-accelerated-liver-fibrosis-in-hiv-hcv-coinfection
#3
Theofilos Chrysanthidis, Georgia Loli, Simeon Metallidis, Georgios Germanidis
Although there is evidence that HCV progresses rapidly in HIV/HCV coinfected patients in comparison with HCV monoinfected, the HIV-, HCV- and host/genetic-related factors, as well as the exact mechanisms implicated in this process are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care and treatment hamper the achievement of this goal. Research on the subject, could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, in order to facilitate and prioritize, not in terms of guidelines but in the real life situation, their treatment with a medically just framework...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28924527/hepatitis-c-screening-the-downstream-dissemination-of-evolving-guidelines-in-a-resident-continuity-clinic
#4
Kamraan Madhani, Ali Aamar, David Chia
Background In 2012, the Centers for Disease Control and Prevention (CDC) published guidelines supporting one-time screening for hepatitis C (HCV) in all persons born between 1945 and 1965. It is estimated that 75% of adults infected with HCV fall within this cohort. Furthermore, it is projected that this preventative health intervention would lead to the diagnosis of 800,000 unknown cases and the prevention of 120,000 deaths. Objectives The primary objectives are to measure adherence to HCV screening in a continuity practice staffed by internal medicine residents and attending physicians and to measure the effect of educational interventions to enhance HCV screening...
July 7, 2017: Curēus
https://www.readbyqxmd.com/read/28922445/position-paper-on-treatment-of-hepatitis-c-in-romania-2017-part-two
#5
Liana Gheorghe, Ioan Sporea, Speranta Iacob, Roxana Sirli, Anca Trifan, Mircea Diculescu, Carol Stanciu, Oliviu Pascu, Monica Acalovschi, Ciprian Brisc, Cristina Cijevschi, Cristian Gheorghe, Zeno Spârchez, Ion Rogoveanu, Daniela Dobru, Dan L Dumitrascu
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments have become available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28922440/real-life-use-of-3-direct-acting-antiviral-regimen-in-a-large-cohort-of-patients-with-genotype-1b-hcv-compensated-cirrhosis
#6
Liana Gheorghe, Speranta Iacob, Manuela Curescu, Ciprian Brisc, Cristina Cijevschi, Florin Caruntu, Carol Stanciu, Iulia Simionov, Ioan Sporea, Cristian Gheorghe, Razvan Iacob, Victoria Arama, Roxana Sirli, Anca Trifan
BACKGROUND AND AIMS: Ombitasvir/Paritaprevir/ritonavir/Dasabuvir (OBV/PTV/r+DSV) is one of the elective direct-acting antivirals (DAAs) recommended by international guidelines and the only one covered by the National Insurance System in Romania until November 2016. Our aim was to present the first prospective Romanian cohort evaluating the effectiveness and safety in clinical practice of this 3DAA combination in patients with HCV genotype-1b Child A liver cirrhosis. METHODS: 681 patients received OBV/PTV/r+DSV+RBV for 12 weeks and were assessed clinically and biologically at baseline, week 4, 8, 12 (end of treatment, EOT), and 12 weeks after therapy (sustained viral response, SVR)...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28914697/are-we-ready-to-treat-hepatitis-c-virus-in-individuals-with-opioid-use-disorder-assessment-of-readiness-in-european-countries-on-the-basis-of-an-expert-generated-model
#7
Nat Wright, Jens Reimer, Lorenzo Somaini, Carlos Roncero, Icro Maremmani, Nicolas Simon, Peter Krajci, Richard Littlewood, Oscar D'Agnone, Hannu Alho, Benjamin Rolland
Individuals with a history of injecting drugs have a high prevalence of chronic hepatitis C (HCV) infection. Many have a history of opioid use disorder (OUD). Despite novel treatments with improved efficacy and tolerability, treatment is limited in the group. A faculty of experts shared insights from clinical practice to develop an HCV care-readiness model. Evidence and expert knowledge was collected. Ten experts developed a model of three factors (with measures): 'healthcare engagement', 'guidance' and 'place'...
September 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28914118/universal-opt-out-screening-for-hepatitis-c-virus-hcv-within-correctional-facilities-is-an-effective-intervention-to-improve-public-health
#8
Meghan D Morris, Brandon Brown, Scott A Allen
Purpose Worldwide efforts to identify individuals infected with the hepatitis C virus (HCV) focus almost exclusively on community healthcare systems, thereby failing to reach high-risk populations and those with poor access to primary care. In the USA, community-based HCV testing policies and guidelines overlook correctional facilities, where HCV rates are believed to be as high as 40 percent. This is a missed opportunity: more than ten million Americans move through correctional facilities each year. Herein, the purpose of this paper is to examine HCV testing practices in the US correctional system, California and describe how universal opt-out HCV testing could expand early HCV detection, improve public health in correctional facilities and communities, and prove cost-effective over time...
September 11, 2017: International Journal of Prisoner Health
https://www.readbyqxmd.com/read/28893101/improving-hepatitis-c-identification-technology-alone-is-not-the-answer
#9
Bruce Nitsche, Sara C Miller, Margaret Giorgio, Carolyn A Berry, Andrew Muir
An estimated 3 to 5 million Americans are chronically infected with hepatitis C virus (HCV), and approximately 75% of those persons were born between 1945 and 1965 (the so-called baby boomer generation). Because of the largely asymptomatic nature of HCV, up to 50% of those infected are unaware of their disease. Risk-based testing has been largely ineffective. Based on prevalence data, the Centers for Disease Control and Prevention and other organizations recommend a onetime HCV antibody test for all baby boomers...
September 1, 2017: Health Promotion Practice
https://www.readbyqxmd.com/read/28872284/hbv-or-hcv-and-pregnancy
#10
Tadeusz Wojciech Łapiński
Despite effective anti-HBV prophylaxis, cases of acute and chronic inflammation are still occurring, including among pregnant women. Studies in Asia suggest considering antiviral treatment among pregnant women with viremia above 10 log6 copies / ml. Current guidelines exclude the use of caesarean section as a method to reduce the likelihood of neonatal infection. At the same time, there are no grounds to ban the breastfeeding of a baby born to an HBV-infected mother. HCV infection can adversely affect the course of pregnancy...
2017: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/28857896/viral-hepatitis-screening-in-transgender-patients-undergoing-gender-identity-hormonal-therapy
#11
Neeraj Mangla, Rifat Mamun, Ilan S Weisberg
BACKGROUND AND AIM: Viral hepatitis is a global health issue and can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Guidelines for viral hepatitis screening in the transgender population do not exist. Transgender patients may be at higher risk for contracting viral hepatitis due to socioeconomic and behavioral factors. The aim of this study was to measure the quality of screening, prevalence, and susceptibility of viral hepatitis, and to identify barriers to screening in transgender patients undergoing gender identity hormonal therapy...
August 29, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28856290/recommendations-for-the-treatment-of-hepatitis-c-in-2017
#12
REVIEW
Waldemar Halota, Robert Flisiak, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Krzysztof Simon, Krzysztof Tomasiewicz
The goals of treatment is to eliminate HCV infection, stop or reverse histological changes, reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the recommendation of the Polish Group of Experts for HCV in 2017 all patients with chronic HCV infection should receive treatment, but it is not recommended in patients at high risk of short overall survival. If access to therapy is restricted, priority should be given to patients whose HCV infection can lead to an unfavourable outcome of the disease within a short time frame, particular to individuals with liver cirrhosis, rapidly progressing liver fibrosis, extrahepatic manifestations of HCV infection, chronic kidney diseases, patients before and after organ transplantation...
June 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28856289/recommendations-for-the-treatment-of-hepatitis-b-in-2017
#13
REVIEW
Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Simon, Krzysztof Tomasiewicz, Marta Wawrzynowicz-Syczewska
The therapeutic goal which is currently unfrequent but realistic in HBV infected patients is sustained HBsAg clearance. It is preceded by the loss or significant suppression of HBV replication and leads to inhibition of the progression of liver fibrosis, normalization of biochemical indicators of liver damage, reduction in the risk of hepatocellular carcinoma, prolongation of survival, prevention of HBV infection in the transplanted organ in post-transplant patients, enhancement of the quality of life, inhibition or reversal of extrahepatic changes associated with HBV infection, and halting of the spread of HBV infections...
June 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28844936/toronto-hcc-risk-index-a-validated-scoring-system-to-predict-10-year-risk-of-hcc-in-patients-with-cirrhosis
#14
Suraj A Sharma, Matthew Kowgier, Bettina E Hansen, Willem Pieter Brouwer, Raoel Maan, David Wong, Hemant Shah, Korosh Khalili, Colina Yim, E Jenny Heathcote, Harry L A Janssen, Morris Sherman, Gideon M Hirschfield, Jordan J Feld
BACKGROUND: Current guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in all patients with cirrhosis, regardless of etiology. However, HCC incidence is not well established for many causes of cirrhosis. AIM: To assess the disease-specific incidence of HCC in a large cohort of patients with cirrhosis and to develop a scoring system to predict HCC risk. METHODS: A derivation cohort of patients with cirrhosis diagnosed by biopsy or non-invasive measures was identified through retrospective chart review...
August 24, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28836363/improving-pharmacotherapy-outcomes-in-patients-with-hepatitis-c-virus-infection-treated-with-direct-acting-antivirals-the-gruvic-project
#15
Esther Chamorro-de-Vega, Carmen Guadalupe Rodriguez-Gonzalez, Alvaro Gimenez-Manzorro, Ana de Lorenzo-Pinto, Irene Iglesias-Peinado, Ana Herranz, Maria Sanjurjo
BACKGROUND/OBJECTIVE: Pharmaceutical care is needed in hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAA). We describe the implementation of a comprehensive pharmaceutical care programme (CPCP) for HCV-infected patients treated with DAA in a tertiary-care hospital and provide data about health outcomes and costs. METHODS: Quasi-experimental study between 1 April 2015 and 30 June 2016. A group of hospital pharmacists collaborating on HCV infection implemented interventional measures for validation of drug prescriptions, detection of clinically relevant drug-drug interactions and adverse drug events (ADEs), and patient education...
August 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28834789/sexual-functioning-in-patients-with-chronic-hepatitis-c-a-systematic-review
#16
Katerina Karaivazoglou, Evangelia-Eirini Tsermpini, Konstantinos Assimakopoulos, Christos Triantos
Chronic hepatitis C virus (HCV) infection is a systematic disease that affects several aspects of patients' well-being, including physical, mental, social, and sexual quality of life. In recent years, there has been a growing body of literature focusing on HCV patients' sexual health, providing evidence of clinically significant and enduring disturbances that disrupt everyday living, but commonly evade clinicians' attention. Relevant studies are characterized by considerable methodological heterogeneity and their findings should be interpreted using a systematic and integrative approach...
August 22, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28810602/hepatitis-c-virus-associated-cryoglobulinemia-with-membrano-proliferative-glomerulonephritis-treated-with-prednisolone-and-interferon-a-case-report
#17
Qiao-Yan Guo, Man Wu, Yang-Wei Wang, Guang-Dong Sun
Hepatitis C virus (HCV) is a major cause of liver-associated morbidity and has an increasing prevalence worldwide. Hepatitis C virus infection may lead to chronic hepatitis, cirrhosis and liver failure. However, it is also associated with a wide range of extra-hepatic complications, such as cryoglobulinemia, an immune complex disease associated with cryoglobulin leading to multiple organ damage and, while the major symptom is vasculitis. The present study reported on a-58-year-old woman who was diagnosed with HCV-associated cryoglobulinemia with skin, kidney and blood system damage and biopsy-proven cryoglobulinemia membrano-proliferative glomerulonephritis...
August 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28782337/diagnosis-management-and-prevention-of-hepatitis-c-in-pakistan-2017
#18
Muhammad Umar, Hamama-Tul-Bushra Khaar, Tayyab Saeed Akhter, Faiza Aslam, Syed Irfan Ahmad, Rai Mohammad Asghar, Mohammad Khurram, Tassawar Hussain, Amjad Salamat, Anwar A Khan, Fazal-E-Hadi, Zahid Mahmood Minhas, Hasnain Ali Shah, Javed Farooqui, Asif Abbas Naqvi, Aftab Mohsin, Waseem-Ud-Din, Sohail Iqbal Bhutta, Sibt Ul Hasnain Syed, Saleem Qureshi, Tashfeen Adam, Moazzam Uddin, Ghias-U-Nabi Tayyab, Najeeb Ul Haq, Atifa Shoaib, Saima Ambreen, Arslan Shahzad, Nadeem Ikram, Gul Nisar, Mohammad Mujeeb Khan, Mohammad Osama
Aims and Objectives: Since the advent of direct acting antiviral agents, there is a revolutionary change in the management of HCV infection. Newer drugs with different mechanism of action are being introduced and are expected to be available in coming few months in Pakistan as well. The main purpose of the guideline is to review and induct the latest research in field of HCV infection in Pakistani perspective so that our healthcare professionals can apply the new recommendations in timely and judicial manner...
October 2016: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28748190/management-of-patients-with-hepatitis-c-virus-monoclonal-gammopathy-of-undetermined-significance-and-multiple-myeloma
#19
Alisse Hannaford, David Del Bello, Siyang Leng, Ajai Chari, Ponni Perumalswami, Douglas Dieterich, Andrea Branch
Background and Aim: The vast majority of the 2.7 million individuals in the United States who are currently infected with hepatitis C virus (HCV) were born between 1945 and 1965. The median age of these patients in this particular generation at the time of this writing was 55 years. In the general population, older age is a risk factor for multiple myeloma (MM) and other monogammopathies. As the baby boomer population ages, HCV providers are increasingly likely to encounter HCV-infected patients with a monoclonal gammopathy...
April 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28745392/-standard-diagnostic-and-therapeutic-approach-to-chronic-hepatitis-c-virus-hcv-infection-guidelines
#20
Petr Urbánek, Petr Husa, J Šperl, S Fraňková, Stanislav Plíšek, Luděk RoŽnovský, P Kümpel
No abstract text is available yet for this article.
March 2017: Klinická Mikrobiologie a Infekc̆ní Lékar̆ství
keyword
keyword
64824
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"